Resmetirom Intermediate (CAS 920509-28-0)
Google Keywords: Resmetirom Intermediate, CAS 920509-28-0, NASH Drug Synthesis, Thyroid Receptor Agonist Intermediates, GMP Pharmaceutical Manufacturing
🌟 Product Overview
Resmetirom Intermediate (CAS 920509-28-0) is a high-quality chemical intermediate critical for the synthesis of Resmetirom, a thyroid hormone receptor-β agonist used in treating non-alcoholic steatohepatitis (NASH) and metabolic disorders. This intermediate ensures efficient, scalable production of Resmetirom API while maintaining strict quality control.
Primary Function: Serves as a key building block in Resmetirom API synthesis, enabling precise chemical transformations.
Applications: NASH drug development, metabolic disorder therapies, and large-scale pharmaceutical manufacturing.
✅ Key Advantages
🔹 High Purity & Consistency | ≥99.0% purity (HPLC/GC verified) | Meets ICH Q11 guidelines for pharmaceutical intermediates.
🔹 Scalability | Optimized for cost-effective large-scale production with minimal by-products.
🔹 Regulatory Compliance | Fully characterized (NMR, HRMS) to support FDA/EMA filings and GMP audits.
🧪 Applications
API Manufacturing: Essential for synthesizing Resmetirom with high yield and purity.
Process Development: Supports R&D in optimizing synthetic routes for improved efficiency.
Analytical Testing: Used in method validation and quality control during API production.
📜 Quality Assurance
Testing Methods: HPLC, GC, NMR, HRMS, and FTIR for structural confirmation and purity analysis.
Standards: Complies with USP <1086>, EP 10.0, and ISO 9001:2015 certified manufacturing processes.
📈 Market Trends
The global NASH treatment market is projected to reach $21.4 billion by 2030 (CAGR 43.2%), driven by increasing liver disease prevalence and demand for targeted therapies. Resmetirom intermediates are pivotal in accelerating the commercialization of innovative NASH drugs.
Drive efficiency in NASH drug production with Resmetirom Intermediate – unparalleled purity, scalability, and compliance for seamless API synthesis.
China
